Nora Pharmaceuticals, developer of women's reproductive health drugs and devices, brought in $25 million in first round financing from Burrill & Co., Prospect Venture Partners and Vivo Ventures. The San Francisco-based company is still pretty stealthy (it doesn't even have a website). It did release that it has some products, but did not specify further.
There is a lot of investor interest in this area of healthcare right now, reports VentureWire. Swiss startup Lumavita, for example, just received $15.4 million to develop treatments for conditions caused by HPV in women. Agile Therapeutics brought in $17.6 million last year to continue work on a once-weekly contraceptive patch. And Interlace Medical raised $7 million for gynecological instruments.